Artificial extracorporeal liver support therapy in patients with severe liver failure

Expert Review of Gastroenterology and Hepatology

Volumn 5, Issue 5, 2011, Pages 591-599

  Rademacher, Sibylle ^a   Oppert, Michael ^a   Jörres, Achim ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

artificial extracorporeal liver support; MARS ; Prometheus ; severe liver failure; SPAD

Indexed keywords

ACUTE LIVER FAILURE; ALBUMIN DIALYSIS; CHOLESTASIS; CHRONIC LIVER FAILURE; CLINICAL EFFECTIVENESS; DETOXIFICATION; DEVICE SAFETY; DISEASE SEVERITY; EXTRACORPOREAL CIRCULATION; HEPATORENAL SYNDROME; HUMAN; INTERMETHOD COMPARISON; INTRACRANIAL PRESSURE MONITORING; LIVER FAILURE; LIVER SUPPORT; MEDICAL INSTRUMENTATION; NONHUMAN; OUTCOME ASSESSMENT; PLASMAPHERESIS; PRURITUS; REVIEW; SURVIVAL RATE; THERAPY EFFECT; TREATMENT INDICATION;

END STAGE LIVER DISEASE; HUMANS; LIVER; LIVER FAILURE, ACUTE; PLASMAPHERESIS; RENAL DIALYSIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 80052817937     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/egh.11.59     Document Type: Review

References (51)

1. Bower WA, Johns M, Margolis HS, Williams IT, Bell BP. Population-based surveillance for acute liver failure. Am. J. Gastroenterol. 102(11), 2459-2463 (2007). (Pubitemid 47631759)
2. Khashab M, Tector AJ, Kwo PY. Epidemiology of acute liver failure. Curr. Gastroenterol. Rep. 9(1), 66-73 (2007). (Pubitemid 46487027)
3. Lee WM, Seremba E. Etiologies of acute liver failure. Curr. Opin. Crit. Care 14(2), 198-201 (2008). (Pubitemid 351498786)
4. Hadem J, Stiefel P, Bahr MJ et al. Prognostic implications of lactate, bilirubin, and etiology in German patients with acute liver failure. Clin. Gastroenterol. Hepatol. 6(3), 339-345 (2008). (Pubitemid 351318381)
5. Gimson AE. Hepatic dysfunction during bacterial sepsis. Intensive Care Med. 13(3), 162-166 (1987). (Pubitemid 17055219)
6. Katoonizadeh A, Laleman W, Verslype C et al. Early features of acute-on-chronic alcoholic liver failure: a prospective cohort study. Gut 59(11), 1561-1569 (2010).
7. Evenepoel P, Laleman W, Wilmer A et al. Detoxifying capacity and kinetics of Prometheus - an new extracorporeal system for the treatment of liver failure. Blood Purif. 23(5), 349-358 (2005). (Pubitemid 41197044)
8. Jalan R, Williams R. Acute-on-chronic liver failure: pathophysiological basis of therapeutic options. Blood Purif. 20(3), 252-261 (2002). (Pubitemid 34195668)
9. Oppert M, Rademacher S, Petrasch K, Jörres A. Extracorporeal liver support therapy with Prometheus in patients with liver failure in the intensive care unit. Ther. Apher. Dial. 13(5), 426-430 (2009).
10. Seige M, Kreymann B, Jeschke B, Schweigart U, Kopp KF, Classen M. Long-term treatment of patients with acute exacerbation of chronic liver failure by albumin dialysis. Transplant Proc. 31(1-2), 1371-1375 (1999). (Pubitemid 29127939)
11. Laleman W, Wilmer A, Evenepoel P, Verslype C, Fevery J, Nevens F. Review article: non-biological liver support in liver failure. Aliment. Pharmacol. Ther. 23(3), 351-363 (2006). (Pubitemid 43382015)
12. Stange J, Ramlow W, Mitzner S, Schmidt R, Klinkmann H. Dialysis against a recycled albumin solution enables the removal of albumin-bound toxins. Artif. Organs 17(9), 809-813 (1993). (Pubitemid 23288693)
13. Larsen FS, Hansen BA, Jorgensen LG, Secher NH, Kirkegaard P, Tygstrup N. High-volume plasmapheresis and acute liver transplantation in fulminant hepatic failure. Transplant Proc. 26(3), 1788 (1994). (Pubitemid 24211782)
14. Pless G. Artificial and bioartifical liver support. Organogenesis 3(1), 20-24 (2007).
15. Peszynski P, Klammt S, Peters E, Mitzner S, Stange J, Schmidt R. Albumin dialysis: single pass vs. recirculation (MARS). Liver 22(Suppl. 2), 40-42 (2002).
16. Mitzner S, Klammt S, Stange J, Schmidt R. Albumin regeneration in liver support - comparison of different methods. Ther. Apher. Dial. 10(2), 108-117 (2006).
17. Krisper P, Stauber R. Technology insight: artificial extracorporeal liver support - how does Prometheus compare with MARS? Nat. Clin. Pract. Nephrol. 3(5), 267-276 (2007). (Pubitemid 46674520)
18. Krisper P, Haditsch B, Stauber R et al. In vivo quantification of liver dialysis: comparison of albumin dialysis and fractionated plasma separation. J. Hepatol. 43(3), 451-457 (2005). (Pubitemid 41111426)
19. Laleman W, Wilmer A, Evenepoel P et al. Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure. Crit. Care 10(4), R108 (2006).
20. Evenepoel P, Laleman W, Wilmer A et al. Prometheus versus molecular adsorbents recirculating system: comparison of efficiency in two different liver detoxification devices. Artif. Organs 30(4), 276-284 (2006).
21. Rifai K. Extracorporeal albumin dialysis. Hepatol. Res. 38(S1), S41-S45 (2008).
22. Doria C, Mandala L, Smith JD et al. Thromboelastography used to assess coagulation during treatment with molecular adsorbent recirculating system. Clin. Transplant. 18(4), 365-371 (2004). (Pubitemid 39077068)
23. Bachli EB, Schuepbach RA, Maggiorini M, Stocker R, Müllhaupt B, Renner EL. Artificial liver support with the molecular adsorbent recirculating system: activation of coagulation and bleeding complications. Liver Int. 27(4), 475-484 (2007). (Pubitemid 46534569)
24. Stadlbauer V, Krisper P, Aigner R et al. Effect of extracorporeal liver support by MARS and Prometheus on serum cytokines in acute-on-chronic liver failure. Crit. Care 10(6), R169 (2006).
25. Rifai K, Ernst T, Kretschmer U, Haller H, Manns MP, Fliser D. Removal selectivity of Prometheus: a new extracorporeal liver support device. World J. Gastroenterol. 12(6), 940-944 (2006).
26. Kramer L, Gendo A, Funk G, Madl C, Falkenhagen D, Gangl A. Clinical experience with artificial liver support in chronic liver failure with encephalopathy. ASAIO J. 46(2), 211 (2000). (Pubitemid 30582350)
27. Ryska M, Laszikova E, Pantoflicek T, Ryska O, Prazak J, Koblihova E. Fractionated plasma separation and adsorption significantly decreases intracranial pressure in acute liver failure: experimental study. Eur. Surg. Res. 42(4), 230-235 (2009).
28. Rifai K, Hafer C, Rosenau J et al. Treatment of severe refractory pruritus with fractionated plasma separation and adsorption (Prometheus). Scand. J. Gastroenterol. 41(10), 1212-1217 (2006). (Pubitemid 44451686)
29. Falkenhagen D, Strobl W, Vogt G et al. Fractionated plasma separation and adsorption system: a novel system for blood purification to remove albumin bound substances. Artif. Organs 23(1), 81-86 (1999). (Pubitemid 29047501)
30. Rifai K, Ernst T, Kretschmer U et al. Prometheus - a new extracorporeal system for the treatment of liver failure. J. Hepatol. 39(6), 984-990 (2003). (Pubitemid 37523770)
31. Rifai K, Ernst T, Kretschmer U et al. The Prometheus device for extracorporeal support of combined liver and renal failure. Blood Purif. 23(4), 298-302 (2005). (Pubitemid 41327801)
32. Herget-Rosenthal S, Lison C, Treichel U et al. Citrate anticoagulated modified fractionated plasma separation and adsorption: first clinical efficiacy and safety data in liver failure. Presented at: The ASN Renal Week 2003. CA, USA, 12-17 November 2003.
33. Meijers BK, Verhamme P, Nevens F et al. Major coagulation disturbances during fractionated plasma separation and adsorption. Am. J. Transplant. 7(9), 2195-2199 (2007). (Pubitemid 47247056)
34. Saliba F, Camus C, Durand F et al. Randomized controlled multicenter trial evaluating the efficacy and safety of albumin dialysis with MARS® in patients with fulminant and subfulminant hepatic failure. Presented at: The 59th Annual meeting of the American Association for the Study of Liver Diseases. CA, USA, 31 October-4 November 2008.
35. Bañares R, Nevens F, Larsen FS et al. Extracorporeal liver support with the molecular adsorbent recirculating system (MARS) in patients with acute-on-chronic liver failure. The RELIEF trial. J. Hepatol. 52(S1), S459-S460 (2010).
36. Rifai K, Kribben A, Gerken G et al. Extracorporeal liver support by fractionated plasma separation and absorption (Prometheus®) in patients with acute-on-chronic liver failure (HELIOS study): a prospective randomized controlled multicenter study. J. Hepatol. 52(S1), S3 (2010).
37. Hassanein TI, Tofteng F, Brown RS Jr et al. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology 46(6), 1853-1862 (2007).
38. Sen S, Davies NA, Mookerjee RP et al. Pathophysiological effects of albumin dialysis in acute-on-chronic liver failure: a randomized controlled study. Liver Transpl. 10(9), 1109-1119 (2004). (Pubitemid 39248408)
39. Heemann U, Treichel U, Loock J et al. Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study. Hepatology 36(4 pt 1), 949-958 (2002).
40. Jung O, Asbe-Vollkopf A, Betz C, Caspary W, Geiger H, Faust D. Long-term therapy of acute chronic liver failure to successful transplantation with an extracorporeal liver support system. Z Gastroenterol. 45(1), 21-24 (2007). (Pubitemid 46202717)
41. Skwarek A, Grodzicki M, Nyckowski P et al. The use Prometheus FPSA system in the treatment of acute liver failure: preliminary results. Transplant. Proc. 38(1), 209-211 (2006).
42. Stadlbauer V, Fickert P, Lackern C et al. Hepatotoxicity of NONI juice: report of two cases. World J. Gastroenterol. 11(30), 4758-4760 (2005). (Pubitemid 41179538)
43. Kramer L, Bauer E, Schenk P, Steininger R, Vigl M, Mallek R. Successful treatment of refractory cerebral oedema in ecstasy/cocaine-induced fulminant hepatic failure using a new high-efficacy liver detoxification device (FPSA- Prometheus). Wien. Klin. Wochenschr. 115(15-16), 599-603 (2003). (Pubitemid 37158290)
44. Sen S, Rose C, Ytrebo LM et al. Effect of albumin dialysis on intracranial pressure increase in pigs with acute liver failure: a randomized study. Crit. Care Med. 34(1), 158-164 (2006). (Pubitemid 43032393)
45. Mitzner SR, Stange J, Klammt S et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl. 6(3), 277-286 (2000). (Pubitemid 30317221)
46. Guevara M, Ginès P. Hepatorenal syndrome. Dig Dis. 23(1), 47-55 (2005). (Pubitemid 40827662)
47. Sen S, Ytrebo LM, Rose C et al. Albumin dialysis: a new therapeutic strategy for intoxication from protein-bound drugs. Intensive Care Med. 30(3), 496-501 (2004). (Pubitemid 38375628)
48. Parés A, Herrera M, Avilés J, Sanz M, Mas A. Treatment of resistant pruritus from cholestasis with albumin dialysis: combined analysis of patients from three centers. J. Hepatol. 53(2), 307-312 (2010).
49. Bellmann R, Freistritzer C, Zoller H et al. Treatment of intractable pruritus in drug induced cholestasis with albumin dialysis: a report of two cases. ASAIO J. 50(4), 387-391 (2004). (Pubitemid 38917890)
50. Schmidt LE, Wang LP, Hansen BA, Larsen FS. Systemic hemodynamic effects of treatment with the molecular adsorbents recirculating system in patients with hyperacute liver failure: a prospective controlled trial. Liver Transpl. 9(3), 290-297 (2003). (Pubitemid 36322332)
51. Khuroo MS, Khuroo MS, Farahat KL. Molecular adsorbent recirculation system for acute and acute-on-chronic liver failure: a meta analysis. Liver Transpl. 10(9), 1099-1106 (2004). (Pubitemid 39248406)